Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8JWZ

Crystal structure of A2AR-T4L in complex with AB928

Summary for 8JWZ
Entry DOI10.2210/pdb8jwz/pdb
Related8JWY
DescriptorAdenosine receptor A2a,Endolysin, OLEIC ACID, SODIUM ION, ... (8 entities in total)
Functional Keywordsadenosine receptor, inhibitor, complex, signaling protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains1
Total formula weight60798.57
Authors
Weng, Y.,Chen, Y.,Xu, Y.,Song, G. (deposition date: 2023-06-29, release date: 2023-08-16, Last modification date: 2024-10-23)
Primary citationWeng, Y.,Yang, X.,Zhang, Q.,Chen, Y.,Xu, Y.,Zhu, C.,Xie, Q.,Wang, Y.,Yang, H.,Liu, M.,Lu, W.,Song, G.
Structural insight into the dual-antagonistic mechanism of AB928 on adenosine A 2 receptors.
Sci China Life Sci, 67:986-995, 2024
Cited by
PubMed Abstract: The adenosine subfamily G protein-coupled receptors AR and AR have been identified as promising cancer immunotherapy candidates. One of the AR/AR dual antagonists, AB928, has progressed to a phase II clinical trial to treat rectal cancer. However, the precise mechanism underlying its dual-antagonistic properties remains elusive. Herein, we report crystal structures of the AR complexed with AB928 and a selective AR antagonist 2-118. The structures revealed a common binding mode on AR, wherein the ligands established extensive interactions with residues from the orthosteric and secondary pockets. In contrast, the cAMP assay and AR and AR molecular dynamics simulations indicated that the ligands adopted distinct binding modes on AR. Detailed analysis of their chemical structures suggested that AB928 readily adapted to the AR pocket, while 2-118 did not due to intrinsic differences. This disparity potentially accounted for the difference in inhibitory efficacy between AR and AR. This study serves as a valuable structural template for the future development of selective or dual inhibitors targeting AR/AR for cancer therapy.
PubMed: 38319473
DOI: 10.1007/s11427-023-2459-8
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.37 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon